New Atlas
•87% Informative
When combined with the original drug, the by-product produced a synergistic effect to inhibit prostate cancer cells.
When used alone, it reduced the buildup of a toxic protein in the brain associated with Parkinson’s disease.
Rucaparib, a drug used to treat ovarian, breast and prostate cancers, is broken down to its major metabolite, M324. CSIC Cell Chemical Biology M324 First M324 30% nine 20 the Spanish National Research Council Fe CSIC ighLightText__NxlGi">rucaparib M324 Rucaparib _NxlGi">rucaparib M324 M324 ">four rucaparib around 40%
VR Score
90
Informative language
92
Neutral language
56
Article tone
informal
Language
English
Language complexity
77
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
2
Source diversity
2
Affiliate links
no affiliate links